AMGN vs. UTHR: Amgen vs. United Therapeutics Stock Comparison

November 11, 2026

How do Amgen (AMGN) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Amgen (AMGN) and United Therapeutics (UTHR)
Profile Item	AMGN	UTHR
Name	Amgen Inc. Common Stock	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	249.05 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	June 17, 1983	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AMGN

UTHR

GSPC

Amgen (AMGN) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Amgen (AMGN) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Amgen (AMGN) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Total Return (1Y)	48.82%	28.77%
Total Return (3Y, Annualized)	24.31%	37.63%
Total Return (5Y, Annualized)	20.67%	23.78%

Risk Profile

Drawdown History

AMGN

UTHR

GSPC

Amgen (AMGN) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Amgen (AMGN) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Volatility (1Y, Annualized)	29.12%	35.00%
Beta (5Y)	0.43	0.49
Max Drawdown (5Y)	-24.86%	-33.00%
Avg. Volume (3M)	2.76M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

AMGN and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Sharpe Ratio (1Y)	1.53	0.70
Sortino Ratio (1Y)	2.36	1.29

Profitability

ROE (TTM)

Both Amgen (AMGN) at 78.35% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max: 109.18%
AMGN: 78.35%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 24.14% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN: 24.14%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max: 83.12%
AMGN: 35.79%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
ROE (TTM)	78.35%	19.13%
ROA (TTM)	8.91%	10.91%
Net Margin (TTM)	24.14%	38.61%
Operating Margin (TTM)	35.79%	28.99%
Gross Margin (TTM)	72.47%	86.34%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while United Therapeutics (UTHR) at 13.07% is closer to the peer norm — faster per-share earnings growth for AMGN.

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Revenue Growth (YoY)	9.95%	10.61%
Revenue Growth (3Y CAGR)	11.77%	18.02%
EPS Growth (YoY)	88.23%	13.07%
EPS Growth (3Y CAGR)	5.52%	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AMGN: 1.48
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Amgen (AMGN) carries debt-to-equity ratio of 3.76 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN: 3.76
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Amgen (AMGN) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; AMGN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Current Ratio (MRQ)	1.48	4.61
Debt / Equity (MRQ)	3.76	--
Net Debt / EBITDA	2.31	-1.53

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN: 2.16%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN: 57.62%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
Dividend Yield (TTM)	2.16%	0.00%
Dividend Payout Ratio (TTM)	57.62%	0.00%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and United Therapeutics (UTHR) at 21.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max: 85.34
Q3: 43.46
AMGN: 26.69
Median: 26.69
Q1: 13.30
Min: 0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max: 58.18
Q3: 25.77
Median: 7.30
AMGN: 6.40
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN: 17.35
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Amgen (AMGN) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and United Therapeutics (UTHR)
Metric	AMGN	UTHR
P/E Ratio (TTM)	26.69	21.22
P/S Ratio (TTM)	6.40	7.51
P/B Ratio (MRQ)	17.35	3.80
Free Cash Flow Yield (TTM)	2.96%	1.90%